Iloprost Therapy in Patients With Critical Limb Ischemia

NCT01458041 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 126

Last updated 2015-03-02

No results posted yet for this study

Summary

Monitoring efficacy and safety aspects of iv. iloprost therapy of patients with critical limb ischemia by recording clinical parameters.

Conditions

  • Peripheral Arterial Disease

Interventions

DRUG

Iloprost (Ilomedin, BAYQ6256)

Prescription and treatment of Iloprost will be decided by physicians

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2014-05-31
Completion
2014-12-31

Countries

  • Hungary

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01458041 on ClinicalTrials.gov